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Summary Early stage intermediate grade non-Hodgkin's lymphoma (NHL) is frequently treated with chemo-
therapy alone or in conjunction with radiotherapy. We have managed clinical Stage I nodal, intermediate
grade NHL with involved field radiotherapy alone for non-bulky (<5 cm post-surgery) disease or combina-
tion chemotherapy alone for more bulky disease.
Forty-three patients were treated between 1978 and 1989. Of the 30 patients with non-bulky disease treated
with radiotherapy, 29 (97%) achieved complete remission (CR). Thirteen (42%) patients relapsed after
radiotherapy and ten of these achieved a further CR (durable in eight) following salvage chemotherapy. Eleven
patients with bulky disease received combination chemotherapy with nine (82%) attaining CR (durable in
eight). Two patients with bulky disease received radiotherapy - both achieved CR, but have relapsed and died
of lymphoma.
Overall actuarial 5 year survival for the total group is 77% with a median follow-up of 30 months (range
3-119 months). The 5 year actuarial survival for the 30 patients with non-bulky disease treated with
radiotherapy is 86% at a median follow-up of 39 months (range 8-119 months). The 4 year actuarial survival
of the 11 patients treated with chemotherapy is 60% with a median follow-up of 25 months (range 3-55
months). We conclude that involved field radiotherapy alone is efficacious for clinical stage I patients with
non-bulky nodal intermediate grade NHL and that patients relapsing after radiotherapy are adequately
salvaged by chemotherapy. Patients with bulky disease have an inferior survival and should receive combina-
tion chemotherapy.
After pathological staging approximately 15% of patients
with diffuse non-Hodgkin's lymphoma (NHL) will have stage
I disease. In the past these patients have been treated with
radiotherapy, but with the introduction of curative chemo-
therapy for intermediate grade NHL in the early 1970's (De
Vita et al., 1975; McKelvey et al., 1976), the use of chemo-
therapy for early stage disease has become more common-
place and the use of radiotherapy alone has declined in many
centres. Chemotherapy alone or in combination with radio-
therapy is now considered by most authorities to be the
treatment of choice for early stage disease (Gaynor & Fisher,
1990).
The efficacy of radiotherapy for patients found to have
stage I disease after meticulous staging including laparotomy
has been documented (Vokes et al., 1985; Levitt et al., 1985)
but few centres would now regard staging laparotomy as a
necessary investigation in the assessment of intermediate
grade NHL. The use of radiotherapy for clinically staged
early disease has been tempered by reports of inadequate
salvage by chemotherapy of patients relapsing after radio-
therapy alone (Vokes et al., 1985; Monfardini et al., 1980;
Kaminski et al., 1986; Armitage & Wen, 1987; Hallahan et
al., 1989; Richards et al., 1989).
Much of the published literature on the management of
early stage NHL is difficult to analyse and compare due to
the frequent practise of combining heterogeneous patient
groups in a single publication. Too often nodal and extra-
nodal disease patients are combined, stage I and II cases are
frequently reported together and histologies with a range of
biological behaviour are not considered separately. The three
treatment options; radiotherapy alone, chemotherapy alone
or combined modality treatment have been utilised incon-
sistently and there are few large randomised trials within this
area of study to aid treatment decisions.
This report outlines the 10-year experience in one centre of
treating clinical stage I, nodal, intermediate grade non-Hodg-
kin's lymphoma and supports the contention that involved
field radiotherapy may still have a useful role in the initial
management of these patients.
Methods
The case records of all patients presenting to the CRC
Wessex Regional Medical Oncology Unit with a diagnosis of
intermediate grade non-Hodgkin's lymphoma between 1978
and 1989 were reviewed. Patients with stage I disease con-
fined to lymph nodes were selected for further study. Patients
with the mediastinum as the only site of disease were not
included as these cases have a distinct and more aggressive
clinical course (Jacobsen et al., 1988; Tedeschini et al., 1990).
The histology of each case was reviewed and classified
according to the Working Formulation (Non-Hodgkin's
Lymphoma Classification Project, 1982). Histological groups
included were diffuse small cleaved (DSC), follicular large
cell (FLC), diffuse mixed (DM), and diffuse large cell (DLC).
All cases were staged according to the Ann Arbor criteria
(Carbone et al., 1971). Each patient was investigated with a
full blood count, biochemistry screen, chest X-ray, bone
marrow aspirate, unilateral bone marrow trephine and assess-
ment of abdominal sites with ultrasound and either bipedal
lymphangiography or computerised tomography (CT). Stag-
ing laparotomy was not performed.
A consistent treatment policy was established at the begin-
ning of the study period. Stage I patients were treated with
involved field radiotherapy alone, to a planned total dose of
at least 35 Gy, if the bulk of disease present after diagnostic
biopsy was 5 cm or less. Radiotherapy was delivered in
225 Gy fractions four or five times per week. Patients with
residual disease > 5 cm were treated with combination
chemotherapy. The induction chemotherapy regimen admini-
stered during the study period was either CHOP (McKelvey
et al., 1976) or CHOP/PEPA (Mead et al., 1987) for six
cycles. Patients relapsing after radiotherapy were treated with
either CHOP, CHOP/PEPA or PEACE/BOM (Sweetenham
et al., 1989) chemotherapy according to the protocol in use at
the time of relapse.
Responses were classified according to UICC criteria,
relapse free survival was calculated from the date of docu-
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mentation of complete remission (CR) until date of last
follow-up or death and overall survival was calculated from
date ofpresentation to this unit until death or last follow-up.
The survival curves were compared according to the log-rank
method (Peto et al., 1977).
Results
Forty-three patients with nodal Stage I intermediate grade
non-Hodgkin's lymphoma were managed in Southampton
during the period under study. Patient characteristics are
displayed in Table I. The median age was 61 years (range
29-85) and 16 (37%) patients were aged 70 years or older.
The most common histological sub-type was diffuse large cell
(present in 65%) and systemic symptoms were present in
only two patients. The overall median duration of follow-up
is 30 months (range 3-119).
Thirty of the 43 patients had non-bulky disease after
biopsy and were treated with involved-field radiotherapy.
Twenty-nine (97%) of these 30 radiotherapy patients achiev-
ed a CR. The remaining patient (an 84 year old man) pro-
gressed during radiotherapy and was considered unsuitable
for combination chemotherapy. He was treated with chlor-
ambucil but died of lymphoma. Two patients with bulky
disease were also treated with radiotherapy as they were
considered medically unfit to receive chemotherapy. Both
patients achieved a CR following radiotherapy, but relapsed
and died of lymphoma 12 and 15 months after presentation.
Thirteen (42%) of the 31 patients achieving CR with
radiotherapy have relapsed at a median time interval of 5
months from the date of CR. With the exception of one
patient with diffuse small cleaved histology in whom relapse
occurred 54 months from CR, all other relapses occurred
within 15 months of completing treatment. Ten (77%) of
these 13 patients attained a second CR following salvage
chemotherapy and this has been maintained in eight patients
with a median follow-up of 37 months (range 6-83 months)
from the time of relapse. Four of the remaining five patients
(including the two patients with bulky disease) are dead of
lymphoma and the 5th patient is alive with disease.
The total radiotherapy dose was 35 Gy in 14 patients,
40 Gy in 10 patients and 45 Gy in two patients. Five patients
received less than the planned total dose. Of these five
patients, one progressed on treatment (after 16Gy) and the
remaining four patients received 30Gy. Two of these four
patients are in continuous CR at 26 + and 28 + months
respectively. One patient relapsed after 11 months and is in
CR 39 + months following salvage chemotherapy. The
Table I Patient characterstics
Variable No. Percentage
Age: <40 7 16%
40-60 15 35%
>60 21 49%
Sex: Male 26 60%
Female 17 40%
B Symptoms: Yes 2 5%
No 41 95%




Bulk disease: <5 cm 30 70%
5-9cm 7 16%
> 10 cm 6 14%






DLC = diffuselargecell; DM = diffusemixed; FLC = follicularlarge
cell; DSC = diffuse small cleaved.
remaining patient, aged 84, relapsed and died of lymphoma.
Table II summarises the sites of relapse of the 13 patients
relapsing after achieving CR with radiotherapy. There were
equal numbers relapsing in nodal only, extranodal only and
nodal plus extranodal sites. Only two (15%) out of 13
relapses were within the treated field giving an overall local
control rate of 91% for the radiotherapy treated patients.
Three patients relapsed in adjacent nodal sites only.
The remaining 11 patients who had bulky stage I disease
received combination chemotherapy as initial treatment. Six
(56%) of this group had disease bulk > 10 cm. They were
predominantly elderly as a group with 8/11 (73%) patients
aged 70 or over compared with 8/32 (25%) of the radio-
therapy patients. Eight patients received the CHOP regimen,
two patients were treated with CHOP/PEPA and one patient
with cardiomegaly had etoposide substituted for doxorubicin
in the CHOP regimen. Three patients (aged 74, 77 and 85)
received less than six cycles of chemotherapy due to poor
tolerance of side-effects (three, four and four cycles respec-
tively). Two of these patients were then treated with involved
field radiotherapy and one patient was observed after CT
scanning confirmed a complete remission. No patient comp-
leting six cycles of chemotherapy received additional
radiotherapy. No patients received more than six cycles of
chemotherapy.
Nine of the 11 (82%) chemotherapy patients achieved a
CR. One patient died of progressive disease in the central
nervous system during chemotherapy and the patient with
cardiomegaly died suddenly at home after four cycles of
chemotherapy. She had responding disease but a post-
mortem was not performed. One patient relapsed 9 months
after obtaining complete remission and died of lymphoma.
The remaining patients are alive and disease-free with a
median follow-up of 25 months.
Figure 1 displays the actuarial survival for the whole
group. Overall 35 (82%) out of 43 patients are alive. The 5
year actuarial survival is 77% with a median follow up of 30
months (range 3-119 months) Figure 2 shows the actuarial
survival analysed by disease bulk. For the 30 patients with
non-bulky disease treated with involved-field radiotherapy
Table II Relapses after radiotherapy
Site ofrelapse:
Outside field only - 11
Inside field only - I
Inside and outside field - 1
13
Nodal site only - 5a
Extranodal site only - 5b
Nodal + extranodal site - 3
13
aOnein-field; threeinadjacentnodes; one intransdiaphragmatic site.












Figure 1 Overall survival curve for patients with Stage I
intermediate grade NHL.
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Figure 2 Overall survival curve for all patients with bulky or
non-bulky disease.
<50 N = 13
I
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Figure 4 The effect of age at presentation on overall survival.
the 5 year actuarial survival is 86% with a median follow-up
of 39 months (range 8-119 months). Figure 3 shows the
freedom from progression survival curve analysed by disease
bulk. Although the freedom from progression rate is equiva-
lent for the two groups, patients with non-bulky disease have
a statistically significant longer overall survival (P = 0.0125)
as a result of chemotherapy salvage of patients relapsing
following radiotherapy. Figure 4 demonstrates the effect of
age on overall survival.
Discussion
A review of the literature reveals that patients with early
stage NHL determined on clinical grounds treated with
radiotherapy alone experience 5 year freedom from relapse
and overall survival rates of between 35-58% and 59-78%
respectively (Kaminski et al., 1986; Peckham et al., 1975;
Chen et al., 1979; Lamb et al., 1984; Mauch et al., 1985).
Many of these studies included stage II patients. In patho-
logical stage I patients treated with radiotherapy alone the
freedom from relapse rates are between 66-100% and the
overall survival rates at 5 years vary from 73-100% (Levitt
et al., 1985; Hallshan et al., 1989; Lester et al., 1982; Hoppe
et al., 1985). The radiotherapy fields used varied between and
within these studies. Although involved field radiotherapy
was used in some patients, many received extended field,
whole abdominal or total nodal irradiation. Three of our
patients treated with involved field radiotherapy relapsed in
adjacent nodal sites (see Table II). These patients may have
benefited from extended field radiotherapy but overall sur-
vival in this group was still excellent.
Combination chemotherapy (with or without radiotherapy)
has been shown to have significant efficacy for early stage
intermediate grade NHL. Cabanillas et al. (1985) treated 43
clinical stage I and II patients with chemotherapy alone and
at the time of reporting only 1/11 stage I patient and 7/28

















Figure 3 Freedom from progression curve for patients with
bulky or non-bulky disease achieving CR.
CR. Miller and Jones (1983) reported on 45 clinical stage I
and II patients treated with chemotherapy although 17
patients also received radiotherapy. With a median follow-up
of 41 months, 42 (95%) of these patients are alive with 38
diesease-free. Connors et al. (1987) reported a 99% CR rate
and an 85% survival rate (median follow-up 30 months) with
three cycles of CHOP chemotherapy followed by involved
field radiotherapy for patients with stage I and II inter-
mediate grade NHL. Longo et al. (1989) treated 47 clinical
stage I and IE patients with four cycles of ProMACE-MOPP
followed by involved field radiotherapy and 45 are alive and
in remission with a median follow-up of 42 months. In view
of these excellent results it has been argued that all early
stage patients are best managed with combination chemo-
therapy with or without radiotherapy (Gaynor & Fisher,
1980). Our view is that clinical stage I patients with non-
bulky nodal disease can be successfully managed with radio-
therapy alone.
Many centres argue that radiotherapy alone for stage I
cases should only be considered after pathological staging
with staging laparotomy (Vokes et al., 1985; Bitran et al.,
1977). It is known that between 10-24% of clinical stage I
and II patients will have intra-abdominal disease detected at
staging laparatomy (Hallahan et al., 1987; Lester et al., 1982;
Carde et al., 1984). In view of the significant number of
patients who cannot undergo laparotomy for other medical
reasons, the morbidity and mortality of the procedure, and
the delay in initiating therapy this approach is impractical
and has not been practised widely.
The central concern with administering local radiotherapy
alone is whether combination chemotherapy can salvage
clinically staged patients when occult disseminated disease
progresses. Many groups have reported variable chemo-
therapy salvage results after radiotherapy. Carde et al. (1984)
in an EORTC randomised trial investigating the value of
adding CVP chemotherapy to radiotherapy salvaged all
patients relapsing after radiotherapy alone and as a result
there was no survival difference between the two arms. Halla-
han et al. (1989) reported 7/10 CR's to salvage chemotherapy
but only one was durable. Most other series have reported
CR salvage rates of between 20% and 50% (Monfardini et
al., 1980; Kaminski et al., 1986; Armitage & Wen, 1987;
Richards et al., 1989; Lamb et al., 1984). Our results with
10/13 CR's with salvage chemotherapy and eight long term
remissions (median follow-up 37 months) are better than
many reported series.
It was elected at the outset not to use radiotherapy for
patients with stage II intermediate grade non-Hodgkin's lym-
phoma. There is now sufficient evidence that patients with
stage II disease have an unacceptably poor outcome follow-
ing radiotherapy alone (Vokes et al., 1985; Monfardini et al.,
1980; Kaminski et al., 1986; Hallahan et al., 1989; Peckham
et al., 1975; Lamb et al., 1984; Kantarjian et al., 1984; Reddy
et al., 1989).
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(i.e. extranodal vs nodal) may also be prognostically impor-
tant in NHL. A proportion of cases of extranodal lymphoma
may be cured by surgery alone (Rudders et al., 1978; Free-
man et al., 1972; Hagberg et al., 1989). Patients with local-
ised involvement of gut-associated lymphoid tissue (Rudders
et al., 1978; Gospodarowicz et al., 1987) are reported to have
a better prognosis than patients with other extranodal sites
affected. Patients with Waldeyer's ring involvement (Mill et
al., 1980), primary brain lymphoma (Littman et al., 1975;
Pollack et al., 1989) and lymphoma of the testis (Duncan et
al., 1980; Doll et al., 1986; Martenson et al., 1988) have been
reported to have an inferior outcome. The inclusion of cases
of extranodal lymphoma in reports of the management of
early stage NHL may obscure or alter the efficacy of treat-
ment for patients with nodal disease alone. We have there-
fore excluded cases of extranodal lymphoma from this series
as they may be best managed on an individual site by site
basis.
Bulky disease has been identified as an adverse prognostic
factor in some series (Kaminski et al., 1986; Hagberg et al.,
1989; Horwich et al., 1988; Mackintosh et al., 1988; Prestidge
et al., 1988; Shigematsu et al., 1988), but not others (Kantar-
jian et al., 1984; Jones et al., 1989; Taylor et al., 1988). We
selected >5 cm after surgical biopsy as representing bulky
disease and chose to treat those patients with combination
chemotherapy, utilising radiotherapy for non-bulky cases.
Other groups have chosen 7 cm or 10 cm as their cut-off
dimension and it has not always been clear whether this
measurement represented pre- or post-surgical size. We have
not used combined modality therapy for bulky disease and
despite six of our chemotherapy patients having > 1O cm
masses all have attained a CR and none have relapsed.
However median follow-up is only 25 months for the chemo-
therapy group and the numbers are small.
As acceptable survival can be achieved by either radio-
therapy or chemotherapy (with or without radiotherapy) in
patients with stage I nodal NHL other factors may influence
treatment decisions. The choice of treatment may be dictated
by patient preference or anticipated side effects of therapy.
For young patients maintaining fertility or minimising the
risk of treatment-induced malignancy may be a major reason
for avoiding chemotherapy. The site of disease may also
influence treatment decisions with irradiation of abdominal
or cervical nodes producing greater morbidity than sites such
as groin or axilla.
We have reported our experience in managing clinical
stage I nodal intermediate grade non-Hodgkin's lymphoma
using radiotherapy alone for non-bulky disease and combina-
tion chemotherapy for bulky disease. Patients relapsing after
radiotherapy have been adequately salvaged by chemo-
therapy. We have excluded patients with stage II disease,
mediastinal lymphoma, and extranodal sites from our series
to present a more uniform patient group. We would strongly
encourage other centres to present results in a similar fashion
so that realistic comparisons can be made between published
series.
The authors wish to thank doctors throughout the Wessex Region
who have referred patients included in this study. The Wessex
Regional Oncology Unit is supported by the Cancer Research Cam-
paign.
We should also like to thank Jill Baston for her help with the
manuscript.
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